Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Other Accumulated Expenses (2016 - 2026)

Scynexis' (SCYX) quarterly Other Accumulated Expenses came in at $669000.0 in Q2 2026, down 11.62% on a YoY basis from $757000.0 in Q2 2025, and down 17.31% quarter-over-quarter from $809000.0 in Q1 2026.

Analysis

Scynexis (SCYX) Other Accumulated Expenses (2016 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Other Accumulated Expenses for 11 consecutive years, with $669000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Accumulated Expenses fell 11.62% year-over-year to $669000.0; the trailing twelve-month figure through Jun 2026 stood at $669000.0 (down 11.62% YoY), and the FY2025 full-year result was $478000.0, down 39.34% from the prior year.
  • Other Accumulated Expenses declined to $669000.0 in Q2 2026 per SCYX's latest filing, from $809000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $5.8 million in Q4 2022 and bottomed at $478000.0 in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $1.5 million across 5 years, with a median of $955500.0 in 2024.
  • The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 435.34% in 2022, then sank 81.98% in 2023.
  • Over 5 years, Other Accumulated Expenses stood at $5.8 million in 2022, then tumbled by 81.98% to $1.0 million in 2023, then decreased by 24.23% to $788000.0 in 2024, then tumbled by 39.34% to $478000.0 in 2025, then jumped by 39.96% to $669000.0 in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods registered $669000.0, $809000.0, and $478000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Scynexis 58.41 Mn -56.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 669,000.00
Mar 31, 2026 809,000.00
Dec 31, 2025 478,000.00
Sep 30, 2025 895,000.00
Jun 30, 2025 757,000.00
Mar 31, 2025 942,000.00
Dec 31, 2024 788,000.00
Sep 30, 2024 969,000.00
Jun 30, 2024 862,000.00
Mar 31, 2024 546,000.00
Dec 31, 2023 1.04 Mn
Sep 30, 2023 1.94 Mn
Jun 30, 2023 2.65 Mn
Mar 31, 2023 1.54 Mn
Dec 31, 2022 5.77 Mn
Sep 30, 2022 2.58 Mn
Jun 30, 2022 2.22 Mn
Mar 31, 2022 1.89 Mn
Dec 31, 2021 1.08 Mn
Sep 30, 2021 2.15 Mn